Erasca, Inc. Operating Lease Cost
Erasca, Inc. (ERAS) reported Operating Lease Cost of $1.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- Erasca, Inc. operating lease, cost for the quarter ending 2026-06-30 was $1.79M, a 1.10% decline year-over-year.
- Erasca, Inc. operating lease, cost for the quarter ending 2026-03-31 was $1.80M, a 1.75% decline year-over-year.
- Erasca, Inc. operating lease, cost for the quarter ending 2025-12-31 was $1.81M, a 1.36% decline year-over-year.
- Erasca, Inc. operating lease, cost for the quarter ending 2025-09-30 was $1.82M, a 1.25% decline year-over-year.
- Erasca, Inc. operating lease, cost for fiscal 2025 was $7.27M, a 9.31% decline from fiscal 2024.
- Erasca, Inc. operating lease, cost for fiscal 2024 was $8.02M, a 4.92% increase from fiscal 2023.
- Erasca, Inc. operating lease, cost for fiscal 2023 was $7.64M, a 31.79% increase from fiscal 2022.
- Erasca, Inc. operating lease, cost for fiscal 2022 was $5.80M, a 152.17% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.79M 10-Q · filed 2026-08-11 | $3.59M 10-Q · filed 2026-08-11 | $5.40M derived: sum of 3 quarters · filed 2026-08-11 | $7.22M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $1.80M 10-Q · filed 2026-05-11 | $3.61M derived: sum of 2 quarters · filed 2026-05-11 | $5.43M derived: sum of 3 quarters · filed 2026-05-11 | $7.24M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.63M derived: sum of 2 quarters · filed 2026-03-12 | $5.44M derived: sum of 3 quarters · filed 2026-08-11 | $7.27M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $1.82M 10-Q · filed 2025-11-12 | $3.63M derived: sum of 2 quarters · filed 2026-08-11 | $5.46M 10-Q · filed 2025-11-12 | $7.30M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $1.81M 10-Q · filed 2026-08-11 | $3.65M 10-Q · filed 2026-08-11 | $5.48M derived: sum of 3 quarters · filed 2026-08-11 | $7.32M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $1.83M 10-Q · filed 2026-05-11 | $3.67M derived: sum of 2 quarters · filed 2026-05-11 | $5.51M derived: sum of 3 quarters · filed 2026-05-11 | $7.94M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.67M derived: sum of 2 quarters · filed 2026-03-12 | $6.11M derived: sum of 3 quarters · filed 2026-03-12 | $8.02M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $1.84M 10-Q · filed 2025-11-12 | $1.80M 10-Q · filed 2024-11-12 | $4.27M derived: sum of 2 quarters · filed 2025-11-12 | $6.18M 10-Q · filed 2025-11-12 | $6.20M 10-Q · filed 2024-11-12 | $8.13M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $2.43M 10-Q · filed 2025-08-12 | $2.40M 10-Q · filed 2024-08-12 | $4.34M 10-Q · filed 2025-08-12 | $4.30M 10-Q · filed 2024-08-12 | $6.29M derived: sum of 3 quarters · filed 2025-08-12 | $8.19M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $1.91M 10-Q · filed 2025-05-13 | $1.90M 10-Q · filed 2024-05-08 | $3.85M derived: sum of 2 quarters · filed 2025-05-13 | $5.75M derived: sum of 3 quarters · filed 2025-05-13 | $7.66M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $3.84M derived: sum of 2 quarters · filed 2025-03-20 | $5.74M derived: sum of 3 quarters · filed 2025-03-20 | $7.64M 10-K · filed 2025-03-20 | $7.70M 10-K · filed 2024-03-27 | |||
| 2023-09-30 | $1.90M 10-Q · filed 2024-11-12 | $3.80M derived: sum of 2 quarters · filed 2024-11-12 | $5.70M 10-Q · filed 2024-11-12 | $7.60M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $1.90M 10-Q · filed 2024-08-12 | $3.80M 10-Q · filed 2024-08-12 | $5.70M derived: sum of 3 quarters · filed 2024-08-12 | $7.60M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $1.90M 10-Q · filed 2024-05-08 | $3.80M derived: sum of 2 quarters · filed 2024-05-08 | $5.70M derived: sum of 3 quarters · filed 2024-05-08 | $6.70M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $3.80M derived: sum of 2 quarters · filed 2024-03-27 | $4.80M derived: sum of 3 quarters · filed 2024-03-27 | $5.80M 10-K · filed 2024-03-27 | ||||
| 2022-09-30 | $1.90M 10-Q · filed 2023-11-09 | $2.60M 10-Q · filed 2022-11-09 | $2.90M derived: sum of 2 quarters · filed 2023-11-09 | $3.90M 10-Q · filed 2023-11-09 | $5.10M 10-Q · filed 2022-11-09 | $4.60M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $1.00M 10-Q · filed 2023-08-10 | $2.00M 10-Q · filed 2023-08-10 | $2.70M derived: sum of 3 quarters · filed 2023-08-10 | $3.60M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $1.00M 10-Q · filed 2023-05-15 | $1.70M derived: sum of 2 quarters · filed 2023-05-15 | $2.60M derived: sum of 3 quarters · filed 2023-05-15 | $2.98M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.60M derived: sum of 2 quarters · filed 2023-03-23 | $1.99M derived: sum of 3 quarters · filed 2023-03-23 | $2.30M 10-K · filed 2023-03-23 | $2.80M 10-K · filed 2022-03-24 | |||
| 2021-09-30 | $905.00K 10-Q · filed 2022-11-09 | $1.28M derived: sum of 2 quarters · filed 2022-11-09 | $1.60M 10-Q · filed 2022-11-09 | $1.95M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $380.00K 10-Q · filed 2022-08-11 | $742.00K 10-Q · filed 2022-08-11 | $1.04M derived: sum of 3 quarters · filed 2022-08-11 | $1.38M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $361.00K 10-Q · filed 2022-05-12 | $661.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.00M derived: sum of 3 quarters · filed 2022-05-12 | $1.32M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $642.00K derived: sum of 2 quarters · filed 2022-03-24 | $963.00K derived: sum of 3 quarters · filed 2022-03-24 | $1.30M 10-K · filed 2022-03-24 | ||||
| 2020-09-30 | $342.00K 10-Q · filed 2021-11-10 | $663.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.00M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $321.00K 10-Q · filed 2021-08-26 | $661.00K 10-Q · filed 2021-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |